老年AML/高危MDS患者临床分析

Wen-Yan Xu, Fang Wang, Li Liu, Xiu-Hong Ren, Ping-Ping Liu, Hao Zhang, Li Zheng, Song-Song Zhang, Ya-Ru Xu, Zhen-Xing Guo
{"title":"老年AML/高危MDS患者临床分析","authors":"Wen-Yan Xu,&nbsp;Fang Wang,&nbsp;Li Liu,&nbsp;Xiu-Hong Ren,&nbsp;Ping-Ping Liu,&nbsp;Hao Zhang,&nbsp;Li Zheng,&nbsp;Song-Song Zhang,&nbsp;Ya-Ru Xu,&nbsp;Zhen-Xing Guo","doi":"10.19746/j.cnki.issn.1009-2137.2022.05.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the clinical features of acute myeloid leukemia (AML)/high-risk myelodysplastic syndrome (MDS) patients aged over 60 years old.</p><p><strong>Methods: </strong>The clinical data of 61 elderly newly diagnosed patients with AML and high-risk MDS who submitted to the Department of Hematology/Oncology of the First Affiliated Hospital of Tsinghua University from January 2009 to April 16, 2021 were retrospectively analyzed. These patients were divided into chemotherapy group (45 cases) and supportive treatment group (16 cases). The overall survival (OS) was analyzed by Kaplan-Meier method, and the prognostic factors of survival were analyzed by multivariate Cox regression.</p><p><strong>Results: </strong>After 2 cycles of induction chemotherapy, the complete remission (CR) rate was 37.8% (17/45), and overall response rate was 62.2% (28/45) in the chemotherapy group. The median OS in the chemotherapy group and supportive treatment group was 11.3 (0.07-43) and 1.6 (0.33-7.72) months, respectively (P<0.001). The median OS in patients who reached CR or did not reach after 1 cycle of induction chemotherapy was 19.8 (10-30.63) and 8.17 (0.07-43) months, respectively (P<0.05), while after 2 cycles was 22.7 (4.2-43) and 7.26 (0.07-26) months, respectively (P<0.001). Univariate analysis showed that age > 80 years old, CCI score > 2, PS score > 2 and supportive treatment were the adverse prognostic factors for OS. Further multivariate analysis suggested that chemotherapy was the only independent prognostic factor for OS (HR=0.140, 95%CI: 0.048-0.409, P<0.001). In the chemotherapy group, univariate analysis showed that CCI score > 2 and failure to reach CR after induction chemotherapy were poor prognostic factors. Multivariate analysis showed that CCI score > 2 (HR=0.139, 95%CI: 0.050-0.384, P<0.001) and failure to achieve CR after induction chemotherapy (HR=0.103, 95%CI: 0.041-0.259, P<0.001) were the adverse prognostic factors for OS. The patients were tolerant to side-effect of chemotherapy.</p><p><strong>Conclusion: </strong>Appropriate chemotherapy can prolong the survival of elderly patients with AML and high-risk MDS.</p>","PeriodicalId":519535,"journal":{"name":"Zhongguo shi yan xue ye xue za zhi","volume":" ","pages":"1311-1317"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Clinical Analysis of Elderly Patients with AML/High-Risk MDS].\",\"authors\":\"Wen-Yan Xu,&nbsp;Fang Wang,&nbsp;Li Liu,&nbsp;Xiu-Hong Ren,&nbsp;Ping-Ping Liu,&nbsp;Hao Zhang,&nbsp;Li Zheng,&nbsp;Song-Song Zhang,&nbsp;Ya-Ru Xu,&nbsp;Zhen-Xing Guo\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2022.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To analyze the clinical features of acute myeloid leukemia (AML)/high-risk myelodysplastic syndrome (MDS) patients aged over 60 years old.</p><p><strong>Methods: </strong>The clinical data of 61 elderly newly diagnosed patients with AML and high-risk MDS who submitted to the Department of Hematology/Oncology of the First Affiliated Hospital of Tsinghua University from January 2009 to April 16, 2021 were retrospectively analyzed. These patients were divided into chemotherapy group (45 cases) and supportive treatment group (16 cases). The overall survival (OS) was analyzed by Kaplan-Meier method, and the prognostic factors of survival were analyzed by multivariate Cox regression.</p><p><strong>Results: </strong>After 2 cycles of induction chemotherapy, the complete remission (CR) rate was 37.8% (17/45), and overall response rate was 62.2% (28/45) in the chemotherapy group. The median OS in the chemotherapy group and supportive treatment group was 11.3 (0.07-43) and 1.6 (0.33-7.72) months, respectively (P<0.001). The median OS in patients who reached CR or did not reach after 1 cycle of induction chemotherapy was 19.8 (10-30.63) and 8.17 (0.07-43) months, respectively (P<0.05), while after 2 cycles was 22.7 (4.2-43) and 7.26 (0.07-26) months, respectively (P<0.001). Univariate analysis showed that age > 80 years old, CCI score > 2, PS score > 2 and supportive treatment were the adverse prognostic factors for OS. Further multivariate analysis suggested that chemotherapy was the only independent prognostic factor for OS (HR=0.140, 95%CI: 0.048-0.409, P<0.001). In the chemotherapy group, univariate analysis showed that CCI score > 2 and failure to reach CR after induction chemotherapy were poor prognostic factors. Multivariate analysis showed that CCI score > 2 (HR=0.139, 95%CI: 0.050-0.384, P<0.001) and failure to achieve CR after induction chemotherapy (HR=0.103, 95%CI: 0.041-0.259, P<0.001) were the adverse prognostic factors for OS. The patients were tolerant to side-effect of chemotherapy.</p><p><strong>Conclusion: </strong>Appropriate chemotherapy can prolong the survival of elderly patients with AML and high-risk MDS.</p>\",\"PeriodicalId\":519535,\"journal\":{\"name\":\"Zhongguo shi yan xue ye xue za zhi\",\"volume\":\" \",\"pages\":\"1311-1317\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhongguo shi yan xue ye xue za zhi\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2022.05.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhongguo shi yan xue ye xue za zhi","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2022.05.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:分析60岁以上急性髓性白血病(AML)/高危骨髓增生异常综合征(MDS)患者的临床特点。方法:回顾性分析2009年1月至2021年4月16日清华大学第一附属医院血液肿瘤科收治的61例老年新诊断AML合并高危MDS患者的临床资料。患者分为化疗组(45例)和支持治疗组(16例)。采用Kaplan-Meier法分析总生存期(OS),采用多因素Cox回归分析影响生存期的因素。结果:诱导化疗2个周期后,化疗组患者完全缓解率为37.8%(17/45),总缓解率为62.2%(28/45)。化疗组和支持治疗组的中位OS分别为11.3(0.07-43)和1.6(0.33-7.72)个月(P 80岁,CCI评分> 2,PS评分> 2,支持治疗是影响OS的不良预后因素)。进一步的多因素分析显示,化疗是影响OS的唯一独立预后因素(HR=0.140, 95%CI: 0.048 ~ 0.409), P < 2和诱导化疗后未能达到CR为预后不良因素。多因素分析显示CCI评分> 2 (HR=0.139, 95%CI: 0.050 ~ 0.384),结论:适当的化疗可延长老年AML合并高危MDS患者的生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Clinical Analysis of Elderly Patients with AML/High-Risk MDS].

Objective: To analyze the clinical features of acute myeloid leukemia (AML)/high-risk myelodysplastic syndrome (MDS) patients aged over 60 years old.

Methods: The clinical data of 61 elderly newly diagnosed patients with AML and high-risk MDS who submitted to the Department of Hematology/Oncology of the First Affiliated Hospital of Tsinghua University from January 2009 to April 16, 2021 were retrospectively analyzed. These patients were divided into chemotherapy group (45 cases) and supportive treatment group (16 cases). The overall survival (OS) was analyzed by Kaplan-Meier method, and the prognostic factors of survival were analyzed by multivariate Cox regression.

Results: After 2 cycles of induction chemotherapy, the complete remission (CR) rate was 37.8% (17/45), and overall response rate was 62.2% (28/45) in the chemotherapy group. The median OS in the chemotherapy group and supportive treatment group was 11.3 (0.07-43) and 1.6 (0.33-7.72) months, respectively (P<0.001). The median OS in patients who reached CR or did not reach after 1 cycle of induction chemotherapy was 19.8 (10-30.63) and 8.17 (0.07-43) months, respectively (P<0.05), while after 2 cycles was 22.7 (4.2-43) and 7.26 (0.07-26) months, respectively (P<0.001). Univariate analysis showed that age > 80 years old, CCI score > 2, PS score > 2 and supportive treatment were the adverse prognostic factors for OS. Further multivariate analysis suggested that chemotherapy was the only independent prognostic factor for OS (HR=0.140, 95%CI: 0.048-0.409, P<0.001). In the chemotherapy group, univariate analysis showed that CCI score > 2 and failure to reach CR after induction chemotherapy were poor prognostic factors. Multivariate analysis showed that CCI score > 2 (HR=0.139, 95%CI: 0.050-0.384, P<0.001) and failure to achieve CR after induction chemotherapy (HR=0.103, 95%CI: 0.041-0.259, P<0.001) were the adverse prognostic factors for OS. The patients were tolerant to side-effect of chemotherapy.

Conclusion: Appropriate chemotherapy can prolong the survival of elderly patients with AML and high-risk MDS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信